RU2006117790A - Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением - Google Patents
Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением Download PDFInfo
- Publication number
- RU2006117790A RU2006117790A RU2006117790/15A RU2006117790A RU2006117790A RU 2006117790 A RU2006117790 A RU 2006117790A RU 2006117790/15 A RU2006117790/15 A RU 2006117790/15A RU 2006117790 A RU2006117790 A RU 2006117790A RU 2006117790 A RU2006117790 A RU 2006117790A
- Authority
- RU
- Russia
- Prior art keywords
- combination
- rimonabant
- pharmaceutical composition
- dyslipidemia
- diuretic
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 title claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title claims 3
- 208000008589 Obesity Diseases 0.000 title claims 2
- 235000020824 obesity Nutrition 0.000 title claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 12
- 229960003015 rimonabant Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000001882 diuretic effect Effects 0.000 claims 6
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 5
- 239000000480 calcium channel blocker Substances 0.000 claims 5
- 239000003160 antidiuretic agent Substances 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 2
- 229950006323 angiotensin ii Drugs 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 2
- 229960002198 irbesartan Drugs 0.000 claims 2
- 230000007863 steatosis Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Применение римонабанта для получения лекарственного средства, пригодного при лечении и профилактике заболеваний, связанных с ожирением и/или дислипидемиями, выбранных из метаболического синдрома и стеатоза.
2. Применение по п.1 для профилактики и лечения метаболического синдрома.
3. Применение по п.1 для профилактики и лечения стеатоза.
4. Применение по п.1, в котором римонабант комбинируют с другим действующим началом, выбранным из одного из следующих терапевтических классов:
антагонист рецепторов AT1 ангиотензина II, индивидуально или в комбинации с диуретиком или с антагонистом кальция;
ингибитор фермента превращения, индивидуально или в комбинации с диуретиком;
антагонист кальция;
бета-блокатор, индивидуально или в комбинации с диуретиком или антагонистом кальция;
антигиперлипемическое или антигиперхолистеринемическое средство;
антидиабетическое средство;
другой агент против ожирения.
5. Применение по одному из пп.1-4, в котором римонабант используют в дозе от 5 до 50 мг.
6. Фармацевтическая композиция, содержащая в комбинации римонабант и антагонист рецепторов AT1 ангиотензина II, индивидуально или в комбинации с диуретиком.
7. Фармацевтическая композиция по п.6, содержащая в комбинации римонабант и ирбесартан.
8. Фармацевтическая композиция по п.6, содержащая в комбинации римонабант, ирбесартан и гидрохлортиазид.
9. Фармацевтическая композиция, содержащая в комбинации римонабант и ингибитор фермента превращения, индивидуально или в комбинации с диуретиком.
10. Фармацевтическая композиция, содержащая в комбинации римонабант и антагонист кальция.
11. Фармацевтическая композиция, содержащая в комбинации римонабант и бета-блокатор, индивидуально или в комбинации с диуретиком или с антагонистом кальция.
12. Фармацевтическая композиция, содержащая в комбинации римонабант и антигиперхолистеринемическое средство.
13. Фармацевтическая композиция, содержащая в комбинации римонабант и антидиабетическое средство.
14. Фармацевтическая композиция по п.13, содержащая в комбинации римонабант и симвастатин.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0312553A FR2861300B1 (fr) | 2003-10-24 | 2003-10-24 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR0312553 | 2003-10-24 | ||
| FR0314763A FR2861301B1 (fr) | 2003-10-24 | 2003-12-15 | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR0314763 | 2003-12-15 | ||
| FR0401193A FR2861302A1 (fr) | 2003-10-24 | 2004-02-05 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR0401193 | 2004-02-05 | ||
| FR0403252 | 2004-03-26 | ||
| FR0403252A FR2861303A1 (fr) | 2003-10-24 | 2004-03-26 | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008146936/15A Division RU2008146936A (ru) | 2003-10-24 | 2008-11-27 | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006117790A true RU2006117790A (ru) | 2007-12-10 |
| RU2357731C2 RU2357731C2 (ru) | 2009-06-10 |
Family
ID=34426973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006117790/15A RU2357731C2 (ru) | 2003-10-24 | 2004-10-22 | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070072907A1 (ru) |
| EP (1) | EP1680117A2 (ru) |
| JP (1) | JP2007509113A (ru) |
| KR (1) | KR20060100443A (ru) |
| AR (3) | AR047764A1 (ru) |
| AU (1) | AU2004289078A1 (ru) |
| BR (1) | BRPI0415538A (ru) |
| CA (1) | CA2543582A1 (ru) |
| FR (1) | FR2861303A1 (ru) |
| IL (1) | IL175103A0 (ru) |
| MA (1) | MA28105A1 (ru) |
| ME (1) | MEP10608A (ru) |
| NZ (1) | NZ547375A (ru) |
| RS (1) | RS20060344A (ru) |
| RU (1) | RU2357731C2 (ru) |
| SG (1) | SG149078A1 (ru) |
| TW (1) | TWI286935B (ru) |
| WO (1) | WO2005046689A2 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2007009700A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome |
| WO2007009698A1 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Combination of pyrazoline type cannabinoid receptor antagonist and statin |
| EP1745782A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome |
| WO2007009694A1 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr.Esteve, S.A. | Use of substituted pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome |
| EP1745781A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combination of pyrazoline type cannabinoid receptor antagonist and statin |
| RU2317809C1 (ru) * | 2006-09-19 | 2008-02-27 | Евгений Леонидович Калин | Способ коррекции избыточной массы тела |
| EP1946779A1 (en) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Combination of substituted pyrazolines and agent for treating dyslipidemia |
| EP1985295A1 (en) | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders |
| KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| ES2349838B1 (es) * | 2009-05-04 | 2011-11-15 | Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im | Derivados de pirazol bivalentes como inhibidores de ingesta |
| RU2568896C2 (ru) * | 2013-07-31 | 2015-11-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему |
| US10835501B2 (en) * | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US6592910B1 (en) * | 1999-04-20 | 2003-07-15 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
| FR2799124B1 (fr) * | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| PL368441A1 (en) * | 2001-09-21 | 2005-03-21 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US6864268B2 (en) * | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| AU2003226149A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| HRP20050001A2 (en) * | 2002-07-09 | 2005-08-31 | Bristol-Myers Squibb Company A Delaware (Usa) Corp | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| AU2003253925A1 (en) * | 2002-07-18 | 2004-02-09 | Banyu Pharmaceutical Co., Ltd. | Combination therapy for the treatment of obesity |
| EP1558252B1 (en) * | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| US20050101542A1 (en) * | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
| US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| EP1635813A4 (en) * | 2003-06-06 | 2009-07-01 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA |
| US20070099884A1 (en) * | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| EP1635773A2 (en) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. (a New Jersey corp.) | Combination therapy for the treatment of hypertension |
| RU2006110545A (ru) * | 2003-09-02 | 2007-10-10 | Зольвай Фармасьютикалз Гмбх (De) | Новое медицинское применение избирательных антагонистов св1-рецептора |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| CA2543197A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| US20080044353A1 (en) * | 2004-03-31 | 2008-02-21 | Krause James E | Combination Therapy for Weight Management |
| WO2006002127A1 (en) * | 2004-06-21 | 2006-01-05 | Fairfield Clinical Trials, Llc | Transdermal delivery system for statin combination therapy |
-
2004
- 2004-03-26 FR FR0403252A patent/FR2861303A1/fr not_active Withdrawn
- 2004-10-21 AR ARP040103811A patent/AR047764A1/es not_active Application Discontinuation
- 2004-10-22 NZ NZ547375A patent/NZ547375A/en unknown
- 2004-10-22 BR BRPI0415538-6A patent/BRPI0415538A/pt not_active IP Right Cessation
- 2004-10-22 AU AU2004289078A patent/AU2004289078A1/en not_active Abandoned
- 2004-10-22 TW TW093132275A patent/TWI286935B/zh not_active IP Right Cessation
- 2004-10-22 WO PCT/FR2004/002715 patent/WO2005046689A2/fr not_active Ceased
- 2004-10-22 EP EP04805278A patent/EP1680117A2/fr not_active Withdrawn
- 2004-10-22 RS YUP-2006/0344A patent/RS20060344A/sr unknown
- 2004-10-22 JP JP2006536128A patent/JP2007509113A/ja not_active Withdrawn
- 2004-10-22 RU RU2006117790/15A patent/RU2357731C2/ru not_active IP Right Cessation
- 2004-10-22 SG SG200809686-9A patent/SG149078A1/en unknown
- 2004-10-22 KR KR1020067009975A patent/KR20060100443A/ko not_active Withdrawn
- 2004-10-22 ME MEP-106/08A patent/MEP10608A/xx unknown
- 2004-10-22 CA CA002543582A patent/CA2543582A1/fr not_active Abandoned
-
2006
- 2006-04-23 IL IL175103A patent/IL175103A0/en unknown
- 2006-04-24 MA MA28959A patent/MA28105A1/fr unknown
- 2006-04-24 US US11/410,226 patent/US20070072907A1/en not_active Abandoned
-
2007
- 2007-11-05 AR ARP070104905A patent/AR063551A2/es unknown
- 2007-11-05 AR ARP070104904A patent/AR063550A2/es unknown
-
2009
- 2009-05-11 US US12/463,652 patent/US20090215755A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA28105A1 (fr) | 2006-08-01 |
| MEP10608A (en) | 2010-06-10 |
| AR063551A2 (es) | 2009-01-28 |
| US20090215755A1 (en) | 2009-08-27 |
| US20070072907A1 (en) | 2007-03-29 |
| RU2357731C2 (ru) | 2009-06-10 |
| EP1680117A2 (fr) | 2006-07-19 |
| RS20060344A (sr) | 2008-08-07 |
| JP2007509113A (ja) | 2007-04-12 |
| TW200526216A (en) | 2005-08-16 |
| WO2005046689A2 (fr) | 2005-05-26 |
| WO2005046689A3 (fr) | 2005-10-13 |
| AR047764A1 (es) | 2006-02-22 |
| TWI286935B (en) | 2007-09-21 |
| NZ547375A (en) | 2009-10-30 |
| CA2543582A1 (fr) | 2005-05-26 |
| BRPI0415538A (pt) | 2006-12-26 |
| SG149078A1 (en) | 2009-01-29 |
| IL175103A0 (en) | 2008-04-13 |
| KR20060100443A (ko) | 2006-09-20 |
| AR063550A2 (es) | 2009-01-28 |
| AU2004289078A1 (en) | 2005-05-26 |
| FR2861303A1 (fr) | 2005-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
| Barreras et al. | Angiotensin II receptor blockers | |
| CA2678958C (en) | Heterocyclic aspartyl protease inhibitors | |
| CN1474690A (zh) | 用于治疗心血管疾病的含有肾素抑制剂的协同性药物联合形式 | |
| GEP20084527B (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| CA2405793A1 (en) | Combination of organic compounds | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| AU6161499A (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| JP2004513920A5 (ru) | ||
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| AR050160A1 (es) | Inhibisores heterociclicos de aspartil proteasa | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| ES2476391T3 (es) | Agentes moduladores de receptor de calcio | |
| JP2020534347A (ja) | Ｓｇｌｔ−２阻害剤とアンジオテンシン受容体拮抗薬を含む医薬組成物 | |
| MX2009005174A (es) | Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| JP2011528669A (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
| WO2005082893A3 (en) | Histamine h3 receptor antagonists, preparation and therapeutic uses | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| JP2009518415A5 (ru) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| AR038858A1 (es) | Combinacion | |
| RU2008146936A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
| ATE399164T1 (de) | Antagonisten des opioidrezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20101023 |